Department of Senological, Gynecological, Plastic and Reconstructive Surgery - Paris Professor Fabrice Lecuru - Institut Curie

Ovarian cancer

  • Ovarian cancer - Prognosis

    Prognosis

    For malignant epithelial tumors.

    The early stages (stages I and some stage II) have an excellent prognosis with a high cure rate. This reinforces the need to diagnose them correctly, by “identifying” them among ovarian cysts. Diagnosis is based on clinical data, second-line ultrasound, MRI and marker assay.

    The surgical intervention is an important stage of their treatment, because it must perform the excision of the tumor (or tumors in the event of a bilateral stage), ideally without intraoperative rupture, but also the staging (assessment of the extension of the tumor) specifies, that is to say multiple samples from the abdominal cavity and the lymph nodes to ensure that there is no extension outside the adnexa. It is essential that the diagnosis be confirmed by a pathologist trained in this pathology. The treatment must be decided by a Multidisciplinary Consultation Meeting (RCP) also trained, which will propose the indications for chemotherapy in a manner adapted to the latest standards.

    The so-called “advanced” stages (stages III and IV) unfortunately remain the most frequent (approximately 75% of patients). The most common notion is that they have a very poor short-term prognosis. However, things have changed over the past 10 years. The coding of surgery with the objective often achieved of carrying out complete resection of the peritoneal localizations, systematic chemotherapy, the addition of bevacizumab (AVASTIN), the systematic diagnosis of germline or tumoral mutations of the BRCA genes then associated with treatment with a PARP inhibitor, more effective treatment of recurrences, supportive care, etc. doubled 5-year survival rates. However, we must be aware that these treatments remain heavy, with a significant impact on the lives of patients and those around them. Tomorrow, immunotherapy and drug combinations will probably make it possible to further improve these results.

About us

After 20 years spent at the Georges Pompidou European Hospital, I preferred to continue my activity at the Institut Curie Paris.

I joined the team of Pr Fabien REYAL (Department of Senological, Gynecological and Reconstructive Surgery)

I follow my activity of Gynecological Oncological Surgery and Recourse Surgery there.

The objective remains to provide the best possible care to women with gynecological cancers,
  - By ensuring the welcome, listening and respect for the quality of life,
  - By providing access to therapeutic innovation and clinical research.
  - Consultations take place on Wednesday afternoon and Friday morning.

Make an appointment

Choose the way you want to make an appointment with Professor Lecuru's service.

Address

Institut Curie Paris

Institutional Partners

  • Chirurgie Curie Institut Curie
  • DIU DIU Européen d'Oncologie Gynécologique et Mammaire
  • SFCO Société Française de Chirurgie Oncologique
  • IMAGYN Initiative des malades atteintes de cancers gynécologiques

Scientific Partners

IMAGYN
ONCOSTREAM
YKSI Production
TMRG
© Copyright - The site is managed in partnership with the French Institute of Gynecology. It is an information and communication tool intended for the general public, patients and health professionals in particular, in accordance with the Code of medical ethics and the recommendations of the National Council of the Order of Physicians, concerning the medical ethics on the health web, adopted in a report of May 22, 2008. The information or advice contained therein is intended to inform the FRENCH public, in simplified terms, of the current state of medical science, its pathways of research and its advances. In no case may this information or advice exonerate health professionals or patients from a real consultation with an anamnesis and a clinical examination, which alone can lead to a diagnosis and a prescription.
Haut